Rhodes Jennifer J 4
4 · ACADIA PHARMACEUTICALS INC · Filed Feb 10, 2026
Research Summary
AI-generated summary of this filing
ACADIA (ACAD) EVP Jennifer Rhodes Sells 6,950 Shares
What Happened
Jennifer J. Rhodes, EVP and Chief Legal Officer of ACADIA Pharmaceuticals, had 12,944 restricted stock units vest and convert to common shares on Feb 6, 2026. To cover tax withholding related to that vesting, 6,950 shares were sold in an open-market sale on Feb 9, 2026 at a weighted average price of $23.38, producing proceeds of $162,491. The remaining 5,994 shares from the vesting were retained.
Key Details
- Transaction dates: 2026-02-06 (RSU vesting/derivative conversion), 2026-02-09 (open-market sale). Form 4 filed 2026-02-10 (timely).
- Sale: 6,950 shares sold; weighted average price $23.38 (range $23.38–$23.40); proceeds $162,491. (F4)
- Vesting/conversion: 12,944 RSUs converted to shares on 2026-02-06 (reported as derivative exercise/conversion, code M). (F1, F5)
- Net retained from this vesting: 5,994 shares (12,944 vested − 6,950 sold).
- Other holdings: Includes 595 shares acquired via employee stock purchase plan on May 15, 2025. (F2)
- Reason for sale: Mandatory sale to cover withholding taxes and related items tied to RSU vesting; intended to comply with Rule 10b5-1(c) requirements. (F3)
Context
This was a routine, tax-withholding sale tied to RSU vesting (a cashless-style outcome) rather than a discretionary open-market sale signaling a view on the stock. For derivative events: RSUs vested and were converted into common shares, with a portion sold to satisfy withholding.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1][F2]2026-02-06+12,944→ 14,559 total - Sale
Common Stock
[F3][F4]2026-02-09$23.38/sh−6,950$162,491→ 7,609 total - Exercise/Conversion
Restricted Stock Units
[F1][F5]2026-02-06−12,944→ 12,945 total→ Common Stock (12,944 underlying)
Footnotes (5)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]Includes 595 shares of the Issuer's common stock acquired by the reporting person on May 15, 2025 pursuant to an employee stock purchase plan.
- [F3]The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.38 to $23.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F5]50% of the restricted stock units vested on February 6, 2026 and 25% vest on each of February 6, 2027 and February 6, 2028.